Sintx Technologies earnings date
Want to see SINT full AI Analyst Report?
Sintx Technologies (SINT) Q2 2026 Earnings Report
SINT Q2 2026 EPS Results
- Actual EPS
- -$0.75
- Consensus EPS
- -$0.73
- Beat/Miss
- Missed by -$0.02
- One Year Ago EPS
- -$0.91
SINT Q2 2026 Revenue Results
- Actual Revenue
- $452.00K
- Expected Revenue
- $460.00K
- Beat/Miss
- Missed by -$8,000
- YoY Revenue Growth
- ―
Earnings Announcement Details
- Quarter
- Q2 2026
- Date
- 08/11/2026
- Time
- After Close
- Conference Call
- Tuesday, August 11, 2026
Q2 2026 Earnings Call Audio
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
The call conveyed meaningful commercial progress: strong year-over-year revenue and product revenue growth, higher gross profit and margins, significant purchase orders (> $3.2M), FDA clearance and first clinical use of the SiNAPTIC wedge, and access to additional financing. However, progress is tempered by persistent net losses, elevated operating cash burn, a low cash balance (~$3.6M), substantial doubt about going concern, increased working capital and G&A expenses, and uncertainty about the timing and conversion of announced orders into recognized revenue. The narrative is constructive on execution and go-to-market priorities but balanced by clear liquidity and execution risks.
The company guided to total revenue of approximately $900,000–$1.1 million in Q3 2026 and approximately $1.0 million–$1.3 million in Q4 2026, noting that this outlook is subject to significant uncertainty around production timing, customer scheduling, manufacturing execution, and revenue recognition; as context, Q2 revenue was $452,000 (product revenue $447,000), up 199% YoY (product revenue +347%), with gross profit $278,000 and gross margin ~61.5%. Management highlighted liquidity and working-capital metrics including cash and cash equivalents of ~$3.6 million at June 30, stockholders’ equity of ~$4.8 million, inventory of $2.3 million (up from $1.0 million), net cash used in operating activities of $5.3 million for the first six months, and net loss of $2.7 million in Q2 ($5.5 million year-to-date); they also noted financing activity totaling roughly $5.0 million in gross proceeds (including ~$4.8 million net financing in H1), ~$1.3 million sold under the ATM with ~$5.1 million remaining capacity, and announced purchase orders aggregating in excess of $3.2 million that, if executed, would drive shipments and revenue into 2027.
- Strong Quarter-over-Quarter Revenue GrowthTotal revenue of $452,000 in Q2 2026, up 199% from $151,000 in Q2 2025; product revenue of $447,000, up 347% from $100,000 a year ago.
- Substantial Gross Profit and Margin ImprovementGross profit increased to $278,000 (up 388% year-over-year) and gross margin improved to ~61.5% compared with 37.7% in the prior year quarter, driven by higher-margin product sales, improved OEM pricing and favorable sales mix.
- Meaningful Purchase Orders Provide Commercial VisibilityReceived purchase orders from multiple contract manufacturing customers with aggregate value exceeding $3.2 million; production and shipments have begun and are expected to continue into 2027 (recognition dependent on execution).
- Regulatory and Early Commercial Milestones for SiNAPTICSiNAPTIC Foot & Ankle Osteotomy Wedge System received FDA 510(k) clearance (late 2025) and saw first U.S. clinical use in March 2026 with initial commercial revenue recognized during limited use review.
- YTD Revenue and Product Revenue MomentumFor the first six months of 2026, total revenue was $832,000 (up 60% year-over-year) and product revenue increased 91% to $747,000; gross profit YTD was $422,000 versus $180,000 a year ago.
- Access to Additional Capital During the QuarterCompleted financing transactions generating approximately $5 million in gross proceeds (June private placement and ATM sales); net cash provided by financing activities was $4.8 million in the first half of 2026, and $1.3 million has been sold under the ATM with ~$5.1 million remaining capacity.
- Provided Near-Term Revenue GuidanceManagement expects Q3 2026 revenue of approximately $900,000 to $1.1 million and Q4 2026 revenue of approximately $1.0 million to $1.3 million, offering a roadmap tied to production and shipment timing.
SINT Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Nov 05, 2026 | 2026 (Q3) | -0.31-0.24 | -3.46 | 93.06% (+3.22) | |
| Aug 11, 2026 | 2026 (Q2) | -0.73-0.75 | -0.91 | 17.58% (+0.16) | |
| Nov 13, 2025 | 2025 (Q3) | -0.55-3.46 | -6.95 | 50.22% (+3.49) | |
| Mar 28, 2024 | 2023 (Q4) | -0.44-0.05 | -17.56 | 99.72% (+17.51) | |
| Mar 30, 2023 | 2022 (Q4) | -6.02-17.53 | -9.5 | -84.53% (-8.03) | |
| Nov 22, 2022 | 2022 (Q3) | -11.00-11.00 | -9 | -22.22% (-2.00) | |
| Mar 25, 2022 | 2021 (Q4) | -1800.00-1900.00 | -1300 | -46.15% (-600.00) | |
| Mar 22, 2021 | 2020 (Q4) | ―-1300.00 | -14600 | 91.10% (+13300.00) | |
| Nov 16, 2020 | 2020 (Q3) | ―-2200.00 | -13600 | 83.82% (+11400.00) | |
| May 13, 2020 | 2020 (Q1) | ―-108.00 | -224.25 | 51.84% (+116.25) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

